ClinicalTrials.gg

Program

tezepelumab

Also written as “Tezepelumab”, “Experimental: Tezepelumab” and “MEDI9929”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Dermatitis, Atopic · Nasal Polyps · Rhinosinusitis, led by 3 companies.

Furthest: phase 4, since Mar 17, 202234 company-led studies, 9 open or runningNext primary completion: Jan 13, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca288 open or runningphase 4since Mar 17, 2022Jul 30, 2013Jan 13, 2027phase 3 · NCT06706817
Amgen50 open or runningphase 2since Jan 10, 2019Sep 18, 2008none ahead
Qilu Pharmaceutical11 open or runningphase 3since Dec 11, 2025Dec 11, 2025Dec 2028phase 3 · NCT07302516

Also a collaborator on its studies: fortrea and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Sep 18, 2008.

  1. Feb 18, 2021Phase 3 study in Nasal PolypsAstraZeneca · NCT04851964 · 416 enrolled · United States, Canada, China and more
  2. Apr 5, 2021Phase 2 study in Chronic UrticariaAmgen · NCT04833855 · 183 enrolled · United States, Canada, France and more
  3. Aug 23, 2021Phase 3 study in Moderate to Severe AsthmaAstraZeneca · NCT05062759 · 70 enrolled · United States
  4. Jan 27, 2022Phase 3 study in AsthmaAstraZeneca · NCT05274815 · 305 enrolled · United States, Argentina, Belgium and more
  5. Mar 17, 2022Phase 4 study in AsthmaAstraZeneca · NCT05329194 · 286 enrolled · United States
  6. May 26, 2022Phase 3 study in AsthmaAstraZeneca · NCT05398263 · 125 enrolled · United States, Brazil, Canada and more
  7. Oct 13, 2022Phase 3 study in Eosinophilic EsophagitisAstraZeneca · NCT05583227 · 368 enrolled · United States, Australia, Austria and more
  8. Jul 20, 2023Phase 3 study in AsthmaAstraZeneca · NCT06023589 · 231 planned · United States, Argentina, Brazil and more
  9. Jun 10, 2024Phase 3 study in AsthmaAstraZeneca · NCT06473779 · 310 enrolled · United States, Argentina, Belgium and more
  10. Nov 7, 2024Phase 3 study in RhinosinusitisAstraZeneca · NCT06706817 · 181 enrolled · United States, Bulgaria, Canada and more
  11. Mar 3, 20252 phase 3 studies in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06883305, NCT06878261
  12. Nov 25, 2025Phase 3 study in AsthmaAstraZeneca · NCT07363642 · 400 planned · China
  13. Dec 11, 2025Qilu Pharmaceutical's first study: phase 3 study in AsthmaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07302516 · 636 planned
  14. Mar 24, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsAstraZeneca · NCT07520162 · 230 planned · China

Ahead

  1. Jan 13, 2027Primary completion: phase 3 study in RhinosinusitisAstraZeneca · NCT06706817
  2. Jun 25, 2027Primary completion: phase 3 study in AsthmaAstraZeneca · NCT06473779
  3. Feb 7, 2028Primary completion: phase 3 study in AsthmaAstraZeneca · NCT07363642
  4. Mar 1, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsAstraZeneca · NCT07520162

TargetBeta

TSLP →read by rule
“Thymic stromal lymphopoietin inhibitor; Thymic stromal lymphopoietin inhibitor”ChEMBL 37, by rule

Other programs on TSLP

ProgramCompanyFurthest phaseStudies
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
felcorekibartGlaxoSmithKlinephase 39
SHR-1905Jiangsu HengRui Medicinephase 37
TQC2731Sino Biopharmaceuticalphase 37
WIN378rulewindward-biophase 22
CDX-622ruleCelldex Therapeuticsphase 12
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07520162Chronic Rhinosinusitis With Nasal Polyps · China3RecruitingAstraZenecaMar 1, 2028230
NCT07302516Asthma3Not yet recruitingQilu PharmaceuticalDec 2028636
NCT07363642Asthma · China3RecruitingAstraZenecaFeb 7, 2028400
NCT06883305Pulmonary Disease, Chronic Obstructive · United States, Brazil, Canada and more3RecruitingAstraZenecaMar 13, 2029990
NCT06878261Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3RecruitingAstraZenecaMar 13, 2029990
NCT06706817Rhinosinusitis · United States, Bulgaria, Canada and more3Active, not recruitingAstraZenecaJan 13, 2027181
NCT06473779Asthma · United States, Argentina, Belgium and more3Active, not recruitingAstraZenecaJun 25, 2027310
NCT06023589Asthma · United States, Argentina, Brazil and more3RecruitingAstraZenecaMay 31, 2028231
NCT05583227Eosinophilic Esophagitis · United States, Australia, Austria and more3Active, not recruitingAstraZenecaJul 14, 2026368
NCT05398263Asthma · United States, Brazil, Canada and more3TerminatedAstraZenecaMar 24, 2025125
NCT05329194Asthma · United States4CompletedAstraZenecaOct 1, 2025286
NCT05274815Asthma · United States, Argentina, Belgium and more3CompletedAstraZenecaSep 9, 2024305
NCT05062759Moderate to Severe Asthma · United States3CompletedAstraZenecaMar 21, 202270
NCT04833855Chronic Urticaria · United States, Canada, France and more2CompletedAmgenDec 20, 2022183
NCT04851964Nasal Polyps · United States, Canada, China and more3CompletedAstraZenecaSep 23, 2024416
NCT04673630Asthma · Hungary, South Africa, United Kingdom1CompletedAstraZenecaSep 27, 202218
NCT04362410Healthy Subjects · China1CompletedAstraZenecaOct 9, 202048
NCT04039113Pulmonary Disease, Chronic Obstructive · United States, Canada, Denmark and more2CompletedAstraZenecaNov 10, 2023337
NCT03989544Asthma · Germany1CompletedAstraZenecaDec 30, 2019315
NCT04048343Asthma · Japan3CompletedAstraZenecaMar 18, 202165
NCT03968978Asthma · United States, Canada, Japan and more3CompletedAstraZenecaJun 5, 2020216
NCT03927157Asthma · China, Philippines, South Korea3CompletedAstraZenecaMay 24, 2024405
NCT03809663Dermatitis, Atopic · United States, Australia, Canada and more2TerminatedAmgenMay 12, 2020251
NCT03706079Asthma · United States, Argentina, Australia and more3CompletedAstraZenecaOct 26, 2021951
NCT03688074Asthma · United States, Canada, Denmark and more2CompletedAstraZenecaNov 16, 2020116
NCT03406078Asthma · United States, Argentina, Germany and more3CompletedAstraZenecaSep 25, 2020150
NCT03347279Asthma · United States, Argentina, Australia and more3CompletedAstraZenecaSep 8, 20201,061
NCT02525094Dermatitis, Atopic · United States, Australia, Canada and more2CompletedAstraZenecaMay 9, 2016113
NCT02512900Asthma · Poland1CompletedAstraZenecaMay 17, 201621
NCT02054130Asthma · United States, Bulgaria, Czechia and more2CompletedAstraZenecaDec 12, 2016584
NCT01913028Healthy · Japan1CompletedAstraZenecaJan 201464
NCT01405963Asthma · Canada1CompletedAmgenApr 5, 201331
NCT00972179Healthy Volunteers1CompletedAmgenJan 9, 201149
NCT00757042Dermatitis, Atopic1CompletedAmgenJan 5, 201178

How it is read

Names in the registry

  • “Tezepelumab”, 23 entries
  • “Experimental: Tezepelumab”, 4 entries
  • “MEDI9929”, 2 entries
  • “tezepelumab (Arm1&Arm2)”, 1 entry
  • “Tezepelumab Dose 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.